Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies - PubMed (original) (raw)
Review
doi: 10.1139/bcb-2014-0107. Epub 2014 Dec 1.
Affiliations
- PMID: 25607236
- DOI: 10.1139/bcb-2014-0107
Review
Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies
Wenguang Chang et al. Biochem Cell Biol. 2015 Oct.
Abstract
The incidence of type 2 diabetes is increasing rapidly worldwide, and the development of novel anti-diabetic drugs is emerging. However, most anti-diabetic drugs cannot be used in patients with hepatic dysfunction, renal disease, and heart disease, which makes pharmacological therapy of type 2 diabetes complicated. Despite continued introduction of novel agents, the search for an ideal drug that is useful as both a hypoglycemic agent and to reduce diabetes-related complications remains elusive. Berberine is an isoquinoline alkaloid extract that has shown promise as a hypoglycemic agent in the management of diabetes in animal and human studies. Mechanistic studies have revealed beneficial effects of berberine on diabetes-related complications. Although there have been few clinical reports of the anti-diabetic effects of berberine, little documentation of adverse effects in humans positions it as a potential candidate drug to treat type 2 diabetes. In the present review, the anti-diabetic mechanism of berberine, its effect on diabetes-related complications, and its recent use in human clinical studies is highlighted. In addition, we summarize the different treatments for type 2 diabetes in adults and children.
Keywords: adenosine-5′-monophosphate kinase; adults; berberine; berbérine; children; complications; diabète sucré de type 2; drug; enfants; hypoglycemic; hypoglycémiant; metabolism; médicament; métabolisme; type 2 diabetes mellitus.
Similar articles
- Metabolomics Study of Type 2 Diabetes Mellitus and the AntiDiabetic Effect of Berberine in Zucker Diabetic Fatty Rats Using Uplc-ESI-Hdms.
Dong Y, Chen YT, Yang YX, Zhou XJ, Dai SJ, Tong JF, Shou D, Li C. Dong Y, et al. Phytother Res. 2016 May;30(5):823-8. doi: 10.1002/ptr.5587. Epub 2016 Feb 16. Phytother Res. 2016. PMID: 26888689 - [Progress of berberine for treatment of type 2 diabetes].
Deng XW, Xie N. Deng XW, et al. Zhongguo Zhong Yao Za Zhi. 2014 Apr;39(8):1374-8. Zhongguo Zhong Yao Za Zhi. 2014. PMID: 25039167 Review. Chinese. - Alteration of hepatic glutathione peroxidase and superoxide dismutase expression in streptozotocin-induced diabetic mice by berberine.
Lao-ong T, Chatuphonprasert W, Nemoto N, Jarukamjorn K. Lao-ong T, et al. Pharm Biol. 2012 Aug;50(8):1007-12. doi: 10.3109/13880209.2012.655377. Pharm Biol. 2012. PMID: 22775417 - Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Pirillo A, Catapano AL. Pirillo A, et al. Atherosclerosis. 2015 Dec;243(2):449-61. doi: 10.1016/j.atherosclerosis.2015.09.032. Epub 2015 Sep 30. Atherosclerosis. 2015. PMID: 26520899 Review.
Cited by
- Role of potential bioactive metabolites from traditional Chinese medicine for type 2 diabetes mellitus: An overview.
Li X, Geng-Ji JJ, Quan YY, Qi LM, Sun Q, Huang Q, Jiang HM, Sun ZJ, Liu HM, Xie X. Li X, et al. Front Pharmacol. 2022 Nov 21;13:1023713. doi: 10.3389/fphar.2022.1023713. eCollection 2022. Front Pharmacol. 2022. PMID: 36479195 Free PMC article. Review. - Enhancement of Berberine Hypoglycemic Activity by Oligomeric Proanthocyanidins.
Zhang H, Wang X, Wang T, Chen K, Wang H, Jia Q, Li Y. Zhang H, et al. Molecules. 2018 Dec 14;23(12):3318. doi: 10.3390/molecules23123318. Molecules. 2018. PMID: 30558158 Free PMC article. - Berberine modulates cisplatin sensitivity of human gastric cancer cells by upregulation of miR-203.
You HY, Xie XM, Zhang WJ, Zhu HL, Jiang FZ. You HY, et al. In Vitro Cell Dev Biol Anim. 2016 Sep;52(8):857-63. doi: 10.1007/s11626-016-0044-y. Epub 2016 May 3. In Vitro Cell Dev Biol Anim. 2016. PMID: 27142767 - The Pathogenesis of Diabetes Mellitus by Oxidative Stress and Inflammation: Its Inhibition by Berberine.
Ma X, Chen Z, Wang L, Wang G, Wang Z, Dong X, Wen B, Zhang Z. Ma X, et al. Front Pharmacol. 2018 Jul 27;9:782. doi: 10.3389/fphar.2018.00782. eCollection 2018. Front Pharmacol. 2018. PMID: 30100874 Free PMC article. Review. - Berberine and Its Study as an Antidiabetic Compound.
Utami AR, Maksum IP, Deawati Y. Utami AR, et al. Biology (Basel). 2023 Jul 8;12(7):973. doi: 10.3390/biology12070973. Biology (Basel). 2023. PMID: 37508403 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical